Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression

To characterise the pattern of late biochemical recurrence (BCR) in the largest contemporary cohort of patients with localised prostate cancer treated with radical prostatectomy (RP) in the active surveillance era.

[1]  K. Kuroiwa,et al.  Predictive factors of late biochemical recurrence after radical prostatectomy , 2017, Japanese journal of clinical oncology.

[2]  L. Salomon,et al.  Conditional Disease-free Survival After Radical Prostatectomy: Recurrence Risk Evolution Over Time. , 2016, Urology.

[3]  Michael Kerger,et al.  Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer , 2015, Nature Communications.

[4]  A. Partin,et al.  Identification of men with the highest risk of early disease recurrence after radical prostatectomy , 2014, The Prostate.

[5]  B. Trock,et al.  Can we stop prostate specific antigen testing 10 years after radical prostatectomy? , 2011, The Journal of urology.

[6]  R. Thompson,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[7]  A. Costello,et al.  Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup , 2011, Pathology.

[8]  D. Penson,et al.  Trends in the treatment of localized prostate cancer using supplemented cancer registry data , 2011, BJU international.

[9]  A. D'Amico,et al.  Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. , 2010, Urology.

[10]  J. Moul,et al.  Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? , 2009, Urology.

[11]  Michael Kerger,et al.  Operative details and oncological and functional outcome of robotic-assisted laparoscopic radical prostatectomy: 400 cases with a minimum of 12 months follow-up. , 2009, European urology.

[12]  H. Miyake,et al.  Significance of micrometastases in prostate cancer. , 2008, Surgical oncology.

[13]  F. Montorsi,et al.  A nomogram predicting long‐term biochemical recurrence after radical prostatectomy , 2008, Cancer.

[14]  A. Zlotta,et al.  European Study of Radical Prostatectomy: time trends in Europe, 1993–2005 , 2007, BJU international.

[15]  A. Partin,et al.  Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Tanabe,et al.  Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.

[17]  T. Daskivich,et al.  Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. , 2006, The Journal of urology.

[18]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[20]  John F Ward,et al.  The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. , 2003, The Journal of urology.

[21]  S. Freedland,et al.  Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. , 2003, Urology.

[22]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[23]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[24]  J. Gschwend,et al.  Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy , 2017, The Journal of urology.

[25]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2014, European urology.

[26]  Timothy J Wilt,et al.  Radical prostatectomy versus observation for localized prostate cancer. , 2012, The New England journal of medicine.